Visiongain says ‘ Global Precision Medicine Market Set To Grow To $83bn By 2022’

01 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Precision Medicine Market Forecast 2018-2028: Companion Diagnostics, Biomarker-based Test, Targeted Therapeutics, Pharmacogenomics, Molecular Diagnostics, Pharmaceuticals & Biotechnology Companies, Diagnostic Companies, Healthcare IT/Big Data Companies, Clinical Laboratories, Cancer, Cardiovascular Diseases, Central Nervous System, Infectious Diseases

Precision medicine is one of the trends in the healthcare industry which has shown tremendous level of progress in the last few years. The focus of healthcare industry has shifted towards personalized medicine, also known as precision medicine or individualized medicine since 2003 with the complete sequencing of human genome. This industry is gaining attention due to the flourishing growth of personal healthcare devices, integration of smart technologies into healthcare, and collaborations of healthcare and IT firms with pharmaceutical and biotechnology companies. The precision medicine data contents and services are accessed by health providers, consumers (patients), and other related users for the improvement of healthcare system and more accurate treatments.

The lead analyst of the report commented “One of the emerging opportunities for the global precision medicine market is the increasing number of patients suffering from genetic diseases in developing countries that include Asia-Pacific countries and many Middle-East and African countries. The growth of the global precision medicine market is dependent on widespread network coverage and access to mobile devices. As the network coverage is expanding at a high rate across the globe, the demand for consumer usage as well as policies to stimulate growth in telecommunications infrastructure is rising.”

Leading companies featured in the report include Abbott Laboratories, GE Healthcare, GlaxoSmithKline (GSK), Johnson & Johnson, Pfizer, Laboratories Corporation of America Holdings, Danaher Corporation

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

“Global Ophthalmic Equipment market set to grow to $75bn by 2024” says new Visiongain report

here is a growing demand for ophthalmic equipment such as vision care products and ophthalmology surgical devices, mainly due to the increasing incidence of myopia across the world.

03 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever